Role of Fas/FasL pathway in the activation of infiltrating cells in murine acute myocarditis caused by Coxsackievirus B3  by Seko, Yoshinori et al.
Role of Fas/FasL Pathway in the
Activation of Infiltrating Cells in Murine
Acute Myocarditis Caused by Coxsackievirus B3
Yoshinori Seko, MD,*†‡ Nobuhiko Kayagaki, PHD,† Ken-ichiro Seino, MD,† Hideo Yagita, PHD,‡
Ko Okumura, PHD,† Ryozo Nagai, MD*
Tokyo, Japan
OBJECTIVES This study was designed to investigate the roles of Fas/FasL pathway in myocardial damage
in murine acute myocarditis caused by Coxsackie virus B3 (CVB3).
BACKGROUND Cardiac myocyte apoptosis rarely occurs in murine acute myocarditis caused by CVB3.
Fas/FasL belong to the tumor necrosis factor receptor/ligand superfamily of costimulatory
molecules and are known to play a critical role in the induction of apoptosis, as well as in the
cytotoxicty mediated by T-cells and natural killer cells.
METHODS We first analyzed the expression of Fas on cardiac myoctyes in vivo and in vitro. Second, we
examined the development of myocardial damage, in C3H/He mice treated with an
anti-FasL monoclonal antibody (mAb), and in C3H/He-lpr/lpr mice and C3H/He-gld/gld
mice infected with CVB3. Third, to investigate the effects of anti-FasL mAb treatment on
the activation of the infiltrating cells, we examined the expression of interferon (IFN)-gamma
and interleukin (IL)-2 as activation markers in the heart of mice by semiquantitative
polymerase chain reaction.
RESULTS Fas was markedly induced on cardiac myocytes with acute myocarditis. Myocardial inflam-
mation was decreased in mice treated with anti-Fas L mAb, C3H/He-lpr/lpr mice and
C3H/He-gld/gld mice. Anti-FasL mAb-treatment also decreased the expression of IFN-
gamma, IL-2, inducible nitric oxide synthase and CVB3 genomes in myocardial tissue.
CONCLUSIONS Our findings strongly suggested that the Fas/FasL pathway played a critical role in the
development of massive myocardial necrosis through activation of infiltrating cells, and raise
the possibility of immunotherapy by blocking the Fas/FasL pathway to prevent myocardial
damage and improve the prognosis of patients with viral myocarditis. (J Am Coll Cardiol
2002;39:1399–403) © 2002 by the American College of Cardiology Foundation
We previously reported that costimulatory molecules be-
longing to the immunoglobulin superfamily and the tumor
necrosis factor receptor/ligand superfamilies play an impor-
tant role in the development of myocardial injury involved
in murine viral myocarditis (1–7). Fas/FasL are the most
well-characterized costimulatory molecules, playing an es-
sential role in the induction of programmed cell death
(apoptosis). They are also known to play an important role
in the cytotoxicity mediated by T-cells and natural killer
(NK) cells (8–10). Although several reports have studied
apoptosis in a murine model of myocarditis and in patients
with myocarditis and dilated cardiomyopathy (11–15), the
percentage of cardiac myocytes affected by apoptosis was too
low to explain the mechanism involved in massive myocar-
dial damage induced by myocarditis. Colston et al. (11)
reported that Coxsackie virus B3 (CVB3)-induced myocar-
ditis did not significantly alter the expression of Fas on
cardiac myocytes of C3H/He mice, supporting the minimal
contribution of apoptosis to myocardial damage. However,
the authors analyzed Fas expression by an ordinary immu-
nohistochemical method using paraffin-embedded samples.
The purpose of the present study was to investigate in more
detail the role of the Fas/FasL pathway in the myocardial
damage induced by myocarditis, with special focus on the
activation of the infiltrating immune cells rather than
apoptosis of cardiac myocytes.
MATERIALS AND METHODS
Animals. Five-week-old male C3H/He mice, C3H/He-
lpr/lpr mice, C3H/He-gld/gld mice and pregnant female
C3H/He mice were purchased from Shizuoka Laboratory
Animal Center (Shizuoka, Japan).
Virus. The preparation of CVB3 (Nancy strain) was as
described previously (3). Five-week-old mice were inocu-
lated intraperitoneally with 1  106 plaque-forming unit of
CVB3 in 0.2 ml phosphate-buffered saline.
Antibodies. Rabbit anti-Fas polyclonal antibody (sc-
1886), which reacts with mouse Fas antigen, was purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, Califor-
nia). The preparation of mouse anti-mouse FasL monoclo-
nal antibody (mAb) (K10, IgG2b) (16) and anticardiac
myosin mAb (CMA19) (17) was previously described.
Polyclonal rabbit anti-asialo GM1 antibody was purchased
from Wako Pure Chemical Industries Ltd. (Osaka, Japan).
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Rat anti-L3T4 mAb (RM4-5) and rat anti-Lyt 2 mAb
(5H10-1) were purchased from PharMingen (San Diego,
California).
In vivo treatment of mice with an anti-FasL mAb. Five-
week-old C3H/He mice received the anti-FasL mAb (K10)
(25 mg/kg intraperitoneally), on the day of virus inoculation
(day 0) and on day 3. Control C3H/He mice received
mouse immunoglobulin G (IgG) (Organon Teknika Cor-
poration, Durham, North Carolina) in the same way.
C3H/He-lpr/lpr mice and C3H/He-gld/gld mice were
simply inoculated with CVB3 without treatment with
anti-FasL mAb (eight mice were used for each group).
Mice were euthanized on day 7, and half of each heart
was fixed in 10% buffered formalin and used for histologic
study. The other half of each heart was freshly frozen in
liquid nitrogen and used for immunohistochemistry and
polymerase chain reaction (PCR).
Histology. The procedures for histologic analysis were as
described previously (3).
Preparation of cultured cardiac myocytes. Cultured ven-
tricular cardiac myocytes were prepared from fetal C3H/He
mice and were treated with recombinant murine interferon
(IFN)-gamma (105 U/l) (Shionogi and Co., Ltd., Tokyo,
Japan) for 48 h, then subjected to immunocytochemical
study as described previously (3).
Immunohistochemistry. In this study, to amplify the spe-
cific signals of antigen-antibody reaction, we used tyramide
signal amplification (TSA) technology for fluorescence
(TSA-Direct [Green], NEN Life Science Products [Bos-
ton, Massachusetts], according to the manufacturer’s in-
structions) for the staining of Fas. The procedures were as
described previously (3).
Double-immunofluorescence. To analyze the phenotypes
of the infiltrating cells expressing FasL, we did double-
immunofluorescent stainings for FasL and asialo GM1 (as a
marker for NK cells), L3T4 (as a marker for T-helper
[Th]-cells) or Lyt 2 (as a marker for cytotoxic T lympho-
cytes [CTLs]). After fixation, the sections were incubated
with rabbit anti-asialo GM1, rat anti-L3T4 or rat anti-Lyt
2 for 1 h at 37°C. After washing in PBS, the sections were
incubated with tetramethylrhodamine isothiocyanate-
conjugated donkey anti-rabbit IgG (Chemicon Interna-
tional Inc., Temecula, California) or goat anti-rat IgG
antibody (EY Laboratories, Inc., San Mateo, California) for
1 h at 37°C, respectively. The subsequent procedures for the
staining of FasL were the same as those for Fas.
Immunocytochemistry. For immunocytochemical analy-
sis, to distinguish cardiac myocytes from nonmuscle cells
(mainly fibroblasts), we performed double-staining for car-
diac myosin heavy chain and Fas as described previously (3).
Preparation of ribonucleic acid (RNA) and complemen-
tary deoxyribonucleic acid (DNA) synthesis. Mice were
euthanized on day 7 after virus inoculation. The procedures
for preparation of total cytoplasmic RNA from the heart
tissues and cDNA synthesis were as described previously
(18).
Amplification of complementary DNA by PCR. To ex-
amine the expression of cytokine messenger RNA in the
heart tissues semiquantitatively, we amplified the single-
stranded complementary DNA in a DNA thermal cycler
(Perkin-Elmer Cetus, Norwalk, Connecticut) with 1 U of
AmpliTaq DNA polymerase (Perkin-Elmer Cetus) using
5- and 3-primers specific for CVB3, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), IFN-gamma, inter-
leukin (IL)-2 and inducible nitric oxide synthase (iNOS),
respectively. The primer sequences, annealing temperature
and the number of cycles for IFN-gamma, IL-2, iNOS and
GAPDH were as described previously (19). For the detec-
tion of CVB3 genomes, we used a 5-sense primer (5-
TCCTCCGGCCCCTGAATGCG-3) and a 3-
antisense primer (3-ACCGACGAATACCACTGTTA-
5) (20). The annealing temperature and the number of
cycles for CVB3 were 60°C and 18 (cycles). The PCR was
performed denaturation at 94°C for 1 min, primer annealing
for 2 min and primer extension at 72°C for 3 min.
Expression of these cytokine messenger RNAs was exam-
ined using ethidium bromide-stained agarose gel electro-
phoresis.
Statistical analysis. Mann-Whitney U test (using p cor-
rected by Dunn’s modulus for multiple comparison) was
used to evaluate differences between the groups.
RESULTS
Expression of Fas in ventricular tissue. In ventricular
tissue of normal mice, Fas was weakly to moderately
expressed by many interstitial cells, which were thought to
be dendritic cells and fibroblasts, almost uniformly distrib-
uted over the myocardium (Fig. 1A). Only slight expression
of Fas was seen on some of cardiac myocytes and almost no
expression was seen on vascular endothelial cells (Fig. 1A
[arrow]). There was also only weak or almost no expression
of Fas on cardiac myocytes of mice on days 1 to 4 (data not
shown). On day 5 after virus inoculation, just after massive
cell infiltrations appeared, expression of Fas was weakly to
moderately induced on the sarcolemma of cardiac myocytes
Abbreviations and Acronyms
CTL  cytotoxic T lymphocyte
CVB3  Coxsackie virus B3
DNA  deoxyribonucleic acid
GAPDH  glyceraldehyde-3-phospate dehydrogenase
IFN  interferon
IgG  immunoglobulin G
IL  interleukin
iNOS  inducible nitric oxide synthase
mAb  monoclonal antibody
NK cell  natural killer cell
PCR  polymerase chain reaction
RNA  ribonucleic acid
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TSA  tyramide signal amplification
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around the cell infiltrations. On day 7, when inflammation
reached a maximum level, expression of Fas was clearly
induced on some of the cardiac myocytes around the cell
infiltrations (Fig. 1B). The infiltrating cells also expressed
Fas. The expression of Fas on cardiac myocytes reached a
maximum level around two weeks after virus inoculation
and continued for more than four weeks with gradual
decrease. Figure 1C (lower magnification) shows that Fas
was extensively expressed on cardiac myocytes over the
myocardium at two weeks after virus inoculation. Higher
magnification confirmed the expression of Fas on the
sarcolemma of cardiac myocytes (Fig. 1D). Many vascular
endothelial cells also strongly expressed Fas at two weeks
after virus inoculation (Fig. 1E [arrows]). Strong expression
of Fas on vascular endothelial cells continued for more than
six weeks (Fig. 1F [arrows]), when the expression of Fas on
cardiac myocytes returned to a low level.
Induction of Fas on cultured cardiac myocytes by IFN-
gamma. Next, to confirm the induction of Fas on cardiac
myocytes, we examined the expression of Fas on cultured
cardiac myocytes treated with IFN-gamma in vitro. Figure
2 shows double-stained cardiac myocytes cultured in a
medium with or without IFN-gamma for 48 h. Figures 2A
and 2B show the staining pattern specific for Fas. Figures
2C and 2D, which correspond to Figures 2A and 2B,
respectively, show the staining pattern specific for cardiac
myosin heavy chain, and indicate that most of the cells were
cardiac myocytes. There was very slight or no expression of
Fas on the cardiac myocytes of the control group (Fig. 2A).
After treatment with IFN-gamma, most of the cardiac
myocytes moderately and clearly expressed Fas on their
surfaces (Fig. 2B). Fas expression was also induced on some
of the nonmuscle cells, which mainly consisted of fibro-
blasts, by treatment with IFN-gamma.
Effects of blockade of Fas/FasL pathway on the devel-
opment of myocardial inflammation. The incidence of
myocarditis was 100% in all groups. Extensive cell infiltra-
tion and necrosis were seen in the mice from Group A
(mouse IgG-treated control group), whereas both cell infil-
tration and necrosis were less severe in the mice from Group
B (anti-FasL mAb-treated group), and were markedly less
severe in the mice from Group C and D (C3H/He-lpr/lpr
and C3H/He-gld/gld group, respectively). The (mean 
SE) percent area of myocardium undergoing inflammation
was decreased (but not statistically significant) in Group B
(6.76  1.36), and was significantly decreased in Group C
(2.98  0.24; p  0.005) and Group D (3.41  0.28; p 
0.005) as compared with Group A (11.31  1.54). This
suggests that anti-FasL mAb-treatment could not com-
pletely inhibit Fas/FasL pathway in vivo. Thus, blockade of
Fas/FasL pathway significantly decreased the myocardial
inflammation induced by CVB3.
Expression of FasL on the infiltrating cells. We analyzed
the phenotypes of FasL-expressing infiltrating cells by
double-immunostaining for FasL and for asialo GM1,
L3T4 or Lyt 2, which were markers for NK cells, Th-cells
and CTLs, respectively, representing most infiltrating cells
at this stage of myocarditis. We found that most of the
infiltrating NK cells, Th-cells and CTLs moderately to
strongly expressed FasL, strongly suggesting that most of
the infiltrating cells could be affected by blockade of
Fas/FasL pathway (data not shown).
Figure 1. Immunohistochemical study for Fas in ventricular tissue. Normal
ventricular myocardium (A) and ventricular myocardium of mice on day 7
(B), at two weeks (C to E) and at six weeks (F) after Coxsackie virus B3
infection were stained with anti-Fas antibody. Bar  20 m.
Figure 2. Immunocytochemical study of cultured cardiac myocytes for Fas.
(A and B) Myocytes in control group (A) and interferon-gamma-treated
group (B), stained with anti-Fas antibody and labeled with fluorescein
isothiocyanate. (C and D) Myocytes stained with a mAb for cardiac
myosin heavy chain (CMA19) and labeled with tetramethylrhodamine
isothiocyanate, corresponding to A and B, respectively. Bar  10 m.
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Effects of anti-FasL mAb-treatment on the expression of
proinflammatory cytokine transcripts and CVB3 ge-
nomes in the ventricular tissues. Next, to investigate the
effects of anti-FasL mAb treatment on the activation of
infiltrating cells, we analyzed the expression of IFN-gamma
and IL-2, which are mainly expressed by the infiltrating
cells and can be good markers for activation (18), as well as
iNOS, which is induced by inflammation and may have a
cytotoxic effect (21,22) and CVB3 genomes. As shown in
Figure 3, the expression of CVB3 genomes was remarkably
decreased in the anti-FasL mAb-treated group (weakly
expressed in only one sample out of six) as compared with
the mouse IgG-treated control group (strongly expressed in
four samples out of six). The expression of IFN-gamma,
IL-2 and iNOS was also significantly decreased in the
anti-FasL mAb-treated group as compared with the mouse
IgG-treated control group. Expression of GAPDH tran-
scripts as internal standard showed that almost equivalent
amounts of RNA were prepared from each mouse.
DISCUSSION
Expression of Fas in myocarditis. In this study, we dem-
onstrated that Fas was markedly induced on cardiac myo-
cytes in murine acute viral myocarditis. The induction of
Fas on cardiac myocytes was confirmed by treatment with
IFN-gamma in vitro. We also found that the expression of
Fas on cardiac myocytes reached a maximum level around
two weeks after virus inoculation, significantly later than
that of other costimulatory molecules and major histocom-
patibility complex antigens (1–3,5,23), which reached a
maximum level on day 7, along with inflammation itself.
However, Fas was also significantly induced on cardiac
myocytes around cell infiltrations on day 7. The reason peak
induction of Fas on cardiac myocytes was delayed is un-
known.
Mechanism of the role of Fas/FasL pathway in myocarditis.
We showed that myocardial inflammation was significantly
decreased in Fas-deficient C3H/He-lpr/lpr mice and FasL-
deficient C3H/He-gld/gld mice infected with CVB3. This
indicates that the Fas/FasL pathway played a critical role in
the development of myocardial damage induced by viral
myocaridits. However, because cardiac myocytes affected by
apoptosis were rare in myocarditis, including this murine
model, we thought that the Fas/FasL pathway might play a
critical role in the activation and cytotoxicity of the infil-
trating T cells and NK cells rather than in inducing
apoptosis of cardiac myocytes. This is strongly supported by
the present data that anti-FasL mAb-treatment signifi-
cantly decreased the expression of IFN-gamma and IL-2,
which are mainly expressed by the infiltrating T cells and
NK cells and can be good markers for activation. This is also
supported by the data that enhanced expression of Fas and
FasL in the hearts of transgenic mice did not cause cardiac
myocyte apoptosis (24). We think that the Fas/FasL ex-
Figure 3. Effects of anti-FasL monoclonal antibody (mAb) treatment on the expression of proinflammatory cytokine transcripts and Coxsackie virus B3
(CVB3) genomes in the ventricular tissues. Total ribonucleic acid was prepared from ventricular tissues of mice from mouse immunoglobulin G
(IgG)-treated control group and anti-FasL mAb-treated group, and analyzed for CVB3, interferon (IFN)-gamma, interleukin (IL)-2, inducible nitric oxide
synthase (iNOS) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcripts by a semiquantitative polymerase chain reaction method.
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pression levels induced by myocarditis might be lower than
the threshold levels for cardiac myocytes to undergo apo-
ptosis. The induction of Fas on cardiac myocytes around cell
infiltrations is thought to enhance the activation of FasL-
expressing infiltrating NK cells and T cells. Therefore,
blockade of Fas/FasL pathway may inhibit cardiac myocyte
necrosis, directly mediated by cytolytic factors such as
perforin (25), by these infiltrating cells. Especially for
CTLs, it was shown that a costimulatory signal through
FasL was essential for antigen-specific maximal prolifera-
tion to occur in vivo as well as in vitro (26,27). Furthermore,
anti-FasL mAb treatment also significantly decreased the
expression of iNOS and CVB3 genomes, indicating that
blockade of the Fas/FasL pathway could decrease inflam-
mation and perforin-mediated cardiac myocyte necrosis
without interfering with the virus clearance. In the present
study, virus clearance seemed to be accelerated rather than
unaffected by blockade of the Fas/FasL pathway. This is
strongly supported by the fact that perforin knockout mice
infected with CVB3 developed less severe myocarditis than
did wild type, and could control the infection and eradicate
the virus (28).
Conclusions. Taken together, our findings strongly sug-
gest that the Fas/FasL pathway plays a critical role in the
development of massive myocardial necrosis rather than
inducing cardiac myocyte apoptosis, and raise the possibility
of immunotherapy by blocking the Fas/FasL pathway to
prevent massive myocardial necrosis and improve the prog-
nosis of patients with viral myocarditis.
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